RODRIGO ABENSUR ATHANAZIO
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
- In-person and online application of the Bronchiectasis Health Questionnaire: are they interchangeable?(2022) LUPPO, Adriano; RACHED, Samia Z.; ATHANAZIO, Rodrigo A.; STELMACH, Rafael; CORSO, Simone Dal
- Automated Computed Tomography Lung Densitometry in Bronchiectasis Patients(2022) SAWAMURA, Marcio Valente Yamada; ATHANAZIO, Rodrigo Abensur; NUCCI, Maria Cecilia Nieves Teixeira Maiorano de; RACHED, Samia Zahi; CUKIER, Alberto; STELMACH, Rafael; ASSUNCAO- JR., Antonildes Nascimento; TAKAHASHI, Marcelo Straus; NOMURA, Cesar Higa
- Is cystic fibrosis a risk factor for COVID-19 infection or related complications?(2022) ATHANAZIO, Rodrigo A.
- Brazilian Guidelines for Nutrition in Cystic Fibrosis(2022) NERI, Lenycia de Cassya Lopes; SIMON, Miriam Isabel Souza dos Santos; AMBROSIO, Valeria Laguna Salomao; BARBOSA, Eliana; GARCIA, Monique Ferreira; MAURI, Juliana Ferreira; GUIRAU, Renata Rodrigues; NEVES, Mirella Aparecida; CUNHA, Carolina de Azevedo Pedrosa; NOGUEIRA, Marcelo Coelho; ALVES, Anna Carolina Di Creddo; GURMINI, Jocemara; SERVIDONI, Maria de Fatima; EPIFANIO, Matias; ATHANAZIO, RodrigoObjective: To develop a scientific consensus on nutrition in cystic fibrosis. Methods: Sixteen coordinators elaborated relevant questions on nutritional therapy in cystic fibrosis, which were divided into six sections: nutritional assessment, nutritional recommendations, nutritional intervention, dietary counseling, special situations and enzyme replacement, and gastrointestinal manifestations. Two to three specialists in the field were responsible for each section and obtaining answers formulated based on standardized bibliographic searches. The available literature was searched in the PubMed (R)/MEDLINE database, after training and standardization of search strategies, to write the best level of evidence for the questions elaborated. Issues related to disagreement were discussed until a consensus was reached among specialists, based on the current scientific literature. Results: Forty-two questions were prepared and objectively answered, resulting in a consensus of nutritional therapy in cystic fibrosis. Conclusion: This work enabled establishing a scientific consensus for nutritional treatment of cystic fibrosis patients.
- Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective(2022) ATHANAZIO, Rodrigo Abensur; CERESETTO, Jose Manuel; RIVERA, Luis Javier Marfil; CESARMAN-MAUS, Gabriela; GALVEZ, Kenny; MARQUES, Marcos Areas; TABARES, Aldo Hugo; SANTACRUZ, Carlos Alberto Ortiz; SANTINI, Fernando Costa; CORRALES, Luis; COHEN, Alexander T.Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. On the basis of results from randomized controlled trials, direct oral anticoagulants (DOACs) are now recommended for the treatment of cancer-associated VTE. The decision to use a DOAC requires consideration of bleeding risk, particularly in patients with gastrointestinal (GI) malignancies, the cost-benefit and convenience of oral therapy, and patient preference. While efficacy with apixaban, edoxaban, and rivaroxaban versus dalteparin has been consistent in the treatment of cancer-associated VTE, heterogeneity is evident with respect to major GI bleeding, with an increased risk with edoxaban and rivaroxaban but not apixaban. Although cost and accessibility vary in different countries of Latin America, DOACs should be considered for the long-term treatment of cancer-associated VTE in all patients who are likely to benefit. Apixaban may be the preferred DOAC in patients with GI malignancies and LMWH may be preferred for patients with upper or unresected lower GI tumors. Vitamin K antagonists should only be used for anticoagulation when DOACs and low molecular weight heparin are inaccessible or unsuitable.
- Prevalence of the eosinophilic phenotype among severe asthma patients in Brazil: the BRAEOS study(2022) ATHANAZIO, Rodrigo; STELMACH, Rafael; ANTILA, Martti; SOUZA-MACHADO, Adelmir; ARRUDA, L. Karla; NETO, Alcindo Cerci; SERPA, Faradiba Sarquis; BLANCO, Daniela Cavalet; LIMA, Marina; BIANCHI JUNIOR, Pedro; PENHA, Marcio; RABAHI, Marcelo FouadObjective: To assess the prevalence of the eosinophilic and allergic phenotypes of severe asthma in Brazil, as well as to investigate the clinical characteristics of severe asthma patients in the country. Methods: This was a cross- sectional study of adult patients diagnosed with severe asthma and managed at specialized centers in Brazil. The study was conducted in 2019. Results: A total of 385 patients were included in the study. Of those, 154 had a blood eosinophil count > 300 cells/mm(3) and 231 had a blood eosinophil count of <= 300 cells/mm(3). The median age was 54.0 years, and most of the patients were female, with a BMI of 29.0 kg/m(2) and a history of allergy (81.6%). The prevalence of patients with a blood eosinophil count > 300 cells/mm3 was 40.0% (95% CI: 35.144.9), and that of those with a blood eosinophil count > 300 cells/ mm(3) and a history of allergy was 31.9% ( 95% CI: 27.3-36.6). Age and BMI showed positive associations with a blood eosinophil count > 300 cells/mm(3) (OR = 0.97, p < 0.0001; and OR = 0.96, p = 0.0233, respectively), whereas the time elapsed since the onset of asthma symptoms showed an increased association with a blood eosinophil count > 300 cells/mm(3) (OR = 1.02, p = 0.0011). Conclusions: This study allowed us to characterize the population of severe asthma patients in Brazil, showing the prevalence of the eosinophilic phenotype (in 40% of the sample). Our results reveal the relevance of the eosinophilic phenotype of severe asthma at a national level, contributing to increased effectiveness in managing the disease and implementing public health strategies.